Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

Joshua F. Zeidner, Judith E. Karp

Research output: Contribution to journalReview articlepeer-review


There have been minimal therapeutic advancements in acute myeloid leukemia (AML) over the past 4 decades and outcomes remain unsatisfactory. Alvocidib (formerly flavopiridol) is a multi-serine threonine cyclin-dependent kinase inhibitor with demonstrable in vitro and clinical activity in AML when combined in a timed sequential chemotherapy regimen, FLAM (alvocidib followed by cytarabine continuous infusion and mitoxantrone). FLAM has been evaluated in sequential phase 1 and phase 2 studies in 149 and 256 relapsed/refractory and newly diagnosed non-favorable risk AML patients, respectively, with encouraging findings in both patient populations warranting further investigation. This review highlights the mechanism of action of alvocidib, pre-clinical studies of alvocidib in AML, and the clinical trials evaluating alvocidib alone and in combination with cytotoxic agents (FLAM) in AML.

Original languageEnglish (US)
Pages (from-to)1312-1318
Number of pages7
JournalLeukemia Research
Issue number12
StatePublished - Sep 2 2015


  • Acute myeloid leukemia
  • Alvocidib
  • CDK inhibitors
  • Cyclin dependent kinase
  • FLAM
  • Flavopiridol

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this